Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-na_ive Patients With Psoriatic Arthritis (PsA)

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY（2023）

引用 0|浏览0

暂无评分

关键词

psoriatic arthritis,guselkumab,fatigue,early treatment targets,long-term,double-blind,placebo-controlled

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要